These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 11814780)
21. Discovery of N-(1-ethylpropyl)-[3-methoxy-5-(2-methoxy-4-trifluoromethoxyphenyl)-6-methyl-pyrazin-2-yl]amine 59 (NGD 98-2): an orally active corticotropin releasing factor-1 (CRF-1) receptor antagonist. Hodgetts KJ; Ge P; Yoon T; De Lombaert S; Brodbeck R; Gulianello M; Kieltyka A; Horvath RF; Kehne JH; Krause JE; Maynard GD; Hoffman D; Lee Y; Fung L; Doller D J Med Chem; 2011 Jun; 54(12):4187-206. PubMed ID: 21618986 [TBL] [Abstract][Full Text] [Related]
22. Recent advances in development of imidazo[1,2-a]pyrazines: synthesis, reactivity and their biological applications. Goel R; Luxami V; Paul K Org Biomol Chem; 2015 Mar; 13(12):3525-55. PubMed ID: 25563506 [TBL] [Abstract][Full Text] [Related]
23. In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists. Hartz RA; Ahuja VT; Rafalski M; Schmitz WD; Brenner AB; Denhart DJ; Ditta JL; Deskus JA; Yue EW; Arvanitis AG; Lelas S; Li YW; Molski TF; Wong H; Grace JE; Lentz KA; Li J; Lodge NJ; Zaczek R; Combs AP; Olson RE; Mattson RJ; Bronson JJ; Macor JE J Med Chem; 2009 Jul; 52(14):4161-72. PubMed ID: 19552436 [TBL] [Abstract][Full Text] [Related]
24. Design, synthesis, and SAR of 2-dialkylamino-4-arylpyrimidines as potent and selective corticotropin-releasing factor(1) (CRF(1)) receptor antagonists. Huang CQ; Grigoriadis DE; Liu Z; McCarthy JR; Ramphal J; Webb T; Whitten JP; Xie MY; Chen C Bioorg Med Chem Lett; 2004 May; 14(9):2083-6. PubMed ID: 15080983 [TBL] [Abstract][Full Text] [Related]
26. Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors. Mulvihill MJ; Ji QS; Coate HR; Cooke A; Dong H; Feng L; Foreman K; Rosenfeld-Franklin M; Honda A; Mak G; Mulvihill KM; Nigro AI; O'Connor M; Pirrit C; Steinig AG; Siu K; Stolz KM; Sun Y; Tavares PA; Yao Y; Gibson NW Bioorg Med Chem; 2008 Feb; 16(3):1359-75. PubMed ID: 17983756 [TBL] [Abstract][Full Text] [Related]
27. [SCA 40 and derivatives: new bronchodilators in an imidazo(1,2-a)pyrazine series]. Bonnet PA; Vitse O; Bénezech V; Subra G; Fabréguettes JR; Zanik L; Laurent F; Michel A; Bompart J; Chapat JP Ann Pharm Fr; 1998; 56(4):155-9. PubMed ID: 9770008 [TBL] [Abstract][Full Text] [Related]
28. Synthesis and evaluation of prodrugs of corticotropin-releasing factor-1 (CRF Hartz RA; Vrudhula VM; Ahuja VT; Grace JE; Lodge NJ; Bronson JJ; Macor JE Bioorg Med Chem Lett; 2017 Mar; 27(6):1360-1363. PubMed ID: 28223020 [TBL] [Abstract][Full Text] [Related]
29. Synthesis of substituted imidazopyrazines as ligands for the human somatostatin receptor subtype 5. Contour-Galéra MO; Poitout L; Moinet C; Morgan B; Gordon T; Roubert P; Thurieau C Bioorg Med Chem Lett; 2001 Mar; 11(5):741-5. PubMed ID: 11266182 [TBL] [Abstract][Full Text] [Related]
30. Potency switch between CHK1 and MK2: discovery of imidazo[1,2-a]pyrazine- and imidazo[1,2-c]pyrimidine-based kinase inhibitors. Meng Z; Ciavarri JP; McRiner A; Zhao Y; Zhao L; Reddy PA; Zhang X; Fischmann TO; Whitehurst C; Arshad Siddiqui M Bioorg Med Chem Lett; 2013 May; 23(10):2863-7. PubMed ID: 23587425 [TBL] [Abstract][Full Text] [Related]
31. Use of the Suzuki reaction for the synthesis of aryl-substituted heterocycles as corticotropin-releasing hormone (CRH) antagonists. Cocuzza AJ; Chidester DR; Culp S; Fitzgerald L; Gilligan P Bioorg Med Chem Lett; 1999 Apr; 9(7):1063-6. PubMed ID: 10230641 [TBL] [Abstract][Full Text] [Related]